Aleeto for acute ischemic stroke: a randomized trial
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests a drug called Aleeto in people who have had an acute ischemic stroke (a stroke caused by a blocked blood vessel) within the last 72 hours. It aims to see if Aleeto can improve recovery and reduce disability.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age between 30 and 80 years old.
- Had an ischemic stroke confirmed by a CT or MRI scan within the last 72 hours.
- Stroke symptoms are moderate to severe (NIHSS score 6-24).
- Able to live independently before the stroke (mRS score less than 2).
- No bleeding in the brain, serious liver or kidney problems, or active infections like HIV or hepatitis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether MT200605 can help people who recently had an ischemic stroke (a type of stroke caused by a blocked blood vessel). The drug is given within 24 hours of symptoms starting, and you may join even if you received clot-busting treatment already.
This trial tests a new drug, HRS-4029, given within 3 hours of an ischemic stroke (a stroke caused by a blocked blood vessel). The goal is to see if the drug helps improve recovery.
This trial tests an investigational drug called LT3001 for people who have had an acute ischemic stroke (a type of stroke caused by a blocked blood vessel in the brain). The drug is given within 24 hours of the stroke to help reduce the damage and improve recovery. Participating could offer access to a new treatment option that may help improve outcomes.
This Phase 2 study tests LT3001 to improve recovery after an acute ischemic stroke (a stroke caused by blocked blood flow). It is designed for people who can be treated within 24 hours of symptom onset and who meet specific safety and health requirements.
This trial tests a medicine called edaravone dexborneol for people who have had an acute ischemic stroke (a stroke caused by a blood clot). The goal is to see if it is safe and helps improve recovery when given within 48 hours of the stroke starting.
This trial studies the safety and effectiveness of edaravone, a neuroprotective drug, in people who have had a mild to moderate stroke in the front part of the brain within the last 48 hours. It aims to see if this drug can help protect the brain from further damage.
Hear when a new Acute Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.